RecruitMe Clinical Trial

ADVL1515, A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
Study of Drug in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
Sponsor:Children's Oncology Group
Enrolling:Male and Female Patients
Age Range:Between 1 and 21 years old
IRB Number:AAAR3155
U.S. Government ID:NCT02808650
Contact: Alice Lee, MD: 212-305-5808 / al2041@cumc.columbia.edu
Additional Study Information:

This is a Phase 1 multicenter study of LY2606368, a CHK1/2 inhibitor, in pediatric patients with refractory solid tumors, including CNS tumors. The study treatment is considered experimental because LY2606368 is not approved by the United States (US) Food and Drug Administration (FDA) for treating pediatric patients with refractory solid tumors, including CNS tumors. The purpose of this study is to estimate the maximum tolerated dose of LY2606368. Another objective is to define its toxicities and potential antitumor activity. LY2606368, starting at Dose Level 1 = 80mg/m2, will be administered as an intravenous infusion over 60 minutes every 14 days of a 28-day cycle. Blood samples will be collected to determine how much LY2606368 is in the blood during the study (pharmacokinetics). Disease assessment will be completed before beginning treatment, at the end of Cycle 1, and then every other cycle.

Do You Qualify?
Is your child between the ages of 12 months and 21 years of age?YesNo
Does your child have recurrent or refractory solid tumors including CNS tumors?YesNo
Has your child fully recovered from acute toxic effects of all prior anti-cancer therapy?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Alice Lee, MD
Email: al2041@cumc.columbia.edu
Phone: 212-305-5808